|
Education:
|
1972-1976 |
Duke University, Durham, North Carolina -
Bachelor of Arts |
|
1976-1980 |
Duke
University, Durham, North Carolina - Doctor of Medicine |
Post Graduate Training:
|
1980-1981 |
Surgical Internship, University of
Utah Affiliated Hospitals, Salt
Lake City, Utah |
|
1981-1982 |
Surgical Resident, University of Utah Affiliated Hospitals, Salt
Lake
City, Utah |
|
1983-1987 |
Urology
Resident, University of Texas, Southwestern Medical School
Affiliated Hospitals (Parkland Memorial Hospital, Dallas VA
Hospital, Children’s Medical Center and Baylor University Medical
Center, Dallas, Texas) |
Professional Experience (Academic/Clinical Positions):
|
1982-1983 |
Emergency Room Staff Physician, Uinta County
Memorial Hospital, Evanston, Wyoming |
|
1985-1987 |
Emergency Room Staff Physician (part-time),
Presbyterian
Hospital, Dallas, Texas |
|
1987-1994 |
Private Practice - Urology & Urologic Oncology,
Charlotte,
North
Carolina |
|
1994-present |
Chair, McKay Department of Urology, Carolinas
Medical Center,
Charlotte, North Carolina |
|
1995-2000
|
Clinical Instructor, UNC-Chapel Hill,
Department of Surgery, Chapel Hill, North Carolina |
|
2000-present |
Clinical Associate Professor, UNC-Chapel Hill, Department of
Surgery, Chapel Hill, North Carolina |
|
1995-present |
Member, Expert Advisory Panel on Urology,
United States Pharmacopeial Convention |
Hospital Appointments:
|
1987-present |
Carolinas Medical Center, Charlotte, North
Carolina - Faculty/Urology Department - Active Staff |
|
1987-present |
Charlotte Institute of Rehabilitation,
Charlotte, North Carolina - Courtesy |
|
1987-present |
Mercy Hospital, Charlotte, North Carolina -
Courtesy |
|
1987-present |
Mercy Hospital South, Charlotte, North Carolina
- Courtesy |
|
1987-present |
Presbyterian Hospital, Charlotte, North
Carolina - Courtesy |
|
1987-present |
Presbyterian-Orthopaedic Hospital, Charlotte,
North Carolina - Courtesy |
|
1987-present |
University Hospital, Charlotte, North Carolina
- Courtesy |
Directorships:
|
1991-1994 |
Physician Co-director for Prostate Cancer
Services, Presbyterian Cancer Center, Charlotte, North Carolina |
|
1991-present |
Board of Directors, Medical Mutual Insurance
Company, Raleigh, North Carolina |
|
1993-1996 |
Board of Directors, Bioethics Resources Group,
Charlotte, North Carolina |
Academic Responsibilities:
Chairman of
McKay Department of Urology of Carolinas Medical Center:
1)
Administration of the University of North Carolina Chapel Hill Urology
PGY-4 Resident Rotation at CMC.
2)
Administration and direct clinical instruction of General
Surgery, Family Practice, Internal Medicine residents on their
Urology rotation.
3)
Regular lectures to the Internal Medicine, Family Practice,
OB/GYN,
and PMR residency programs.
4)
Administration of an active clinical research practice that involves 3
full-time clinical research nurses and a basic science prostate cancer
lab run by Laura Glasscock, PhD.
Professional Society Memberships:
|
1987-present |
American Medical Association |
|
1987-present |
North
Carolina Medical Society |
|
1987-present |
Mecklenburg County Medical Society |
|
1990-Present |
Member, American Urological Association
|
|
1994-Present |
Fellow, American College of Surgeons
|
|
2002-Present |
American College of Surgeons Oncology Group
|
|
2003-Present |
Society of Urologic Oncology |
Patents:
Patent No. 5,858,673; Issue Date January 12, 1999
for “Method For Detecting Prostate Cells” Application No. 08/851,135;
Filed May 5, 1997
Sponsored
Clinical Trials, (Local Principal Investigator):
-
Roberts
Protocol #301 – Phase III, Open-Label, Randomized, Parallel,
Active-Control Study to Evaluate Efficacy and Safety of Histrelin
Subdermal Implant in Patients with Advanced Prostate Cancer (Shire
Pharmaceuticals).
-
LIA-INT-26 – An international phase II randomized, double-blind,
multicenter study to determine the tolerability and efficacy of three
different doses of liarozole in patients with rising prostate specific
antigen levels after definitive treatment (Janssen Pharmaceuticals).
-
Abbott
M00-244 – A Phase III, Randomized, Double-Blind, Placebo-Controlled
Study of the Safety and Efficacy of 10 mg. Atrasentan in Men with Non-Metastatic,
Hormone-Refractory Prostate Cancer (Abbott Pharmaceuticals).
-
Abbott
M00-258 – A Phase III Extension Study to Evaluate the Safety of 10 mg.
Atrasentan in Men with Hormone-Refractory Prostate Cancer (Abbott
Pharmaceuticals).
-
Abbott
M01-366 – A Phase II Study Evaluating the Safety and Efficacy of
Atrasentan (ABT-627) in Men with Hormone Naive Prostate Cancer that
are Exhibiting Early Signs of Biochemical Failure (Abbott
Pharmaceuticals).
-
Protocol
No. 301 – A Phase III, Open-Label Study to Evaluate Efficacy and
Safety of Histrelin Subdermal Implant in Patients with Advanced
Prostate Cancer (Hydro Med Sciences).
-
Trial
DC3-HRPC – A Randomized, Double-Blind, Placebo-Placebo-Controlled
Phase III Clinical Trial Evaluating DCVax
ä Prostate Autologous
Dendritic Cells Loaded with Recombinant Prostate Specific Membrane
Antigen (rPSMA) for the Treatment of Metastatic Hormone Refractory
Prostate Cancer (Northwest Biotherapeutics Inc.).
GTX-006-211 – A Phase IIb Study to Determine the Long Term Prostate
Cancer Chemoprevention Efficacy and Safety of GTx-006 in Men with High
Grade Prostate Intraepithelial Neoplasia (PIN) (Health Decision,
Inc.).
Study No.
C-100-12 -- A Multi-Center, Randomized Phase III Study of Adjuvant
Oncophage â Versus Observation
in Patients with High Risk of Recurrence After Surgical Treatment for
Renal Cell Carcinoma (Antigenics, Inc.).
Guilford
Pharmaceuticals: Phase II, Multi-Center, Randomized, Double-Blind,
Placebo-Controlled, 3-Arm, 12-MonthTrial to Evaluate the Effects of
GPI 1485 on Erectile Function in Patients Undergoing BNSRRP for
Prostatic Carcinoma.
REDUCE
ARI4006: A Randomized, Double-Blind, Placebo-Controlled, Parallel
Group Study of the Efficacy and Safety of Dutasteride 0.5mg
Administered Orally Once Daily for Four Years to Reduce the Risk of
Biopsy-Detectable Prostate Cancer (GlaxoSmithKline).
Dendreon
P-11: Autologous PAP-Loaded Dendritic Cell Vaccine (APC8015, Provenge™)
In Patients With Non-Metastatic Prostate Cancer Who Experience PSA
Elevation Following Radical Prostatectomy: A Randomized, Controlled,
Double-Blind Trail (Dendreon Corporation).
D9902B: A
Double-Blind, Randomized, Placebo-Controlled Phase III Trial of
Immunotherapy with Autologous Antigen Presenting Cells Loaded with
PA2024 (Provenge®, APC8015) in Asymptomatic Subjects with Gleason Sum
≤ 7, Metastatic, Androgen Independent Prostatic Adenocarcinomas
(Dendreon Corporation).
PB01: An
Open Label, Single Arm Trial of Immunotherapy with Autologous Antigen
Presenting Cells Loaded with PA2024 (APC8015F) For Subjects with
Objective Disease Progression and Disease-Related Pain on Protocol
D9902 (Dendreon Corporation).
Publications:
1. “Ultrasonic lithotripsy: the risk of hearing loss”. Chris M.
Teigland, Ralph V. Clayman, Ross J. Roeser. Journal of Urology
135:728, 1986.
2. “Functional characteristics of the Camey ileal bladder”.
Claus G. Roehrborn, Chris M. Teigland, Arthur I. Saglowsky.
Journal of Urology 138:739, 1987.
3. “Harnbleitung mittels ileumschlinge nach Camey -
Ergebnisse urogynamischer dutdien”.
Chris M. Teigland
and Claus G. Roehrborn. Aktuelle Urologie 18:11-17, 1987.
4. “Progression of leukoplakia of the bladder to squamous cell
carcinoma 19 years After complete urinary diversion”. Claus G.
Roehrborn, Chris M. Teigland, Harry M. Spence. Journal of
Urology 140:603, 1988.
5. “Simultaneous detection of circulating prostate-specific antigen
(PSA) - expressing and prostate-specific membrane antigen (PSM) -
expressing cells by a multiplex reverse transcriptase polymerase chain
reaction (RT-PCR) assay”. Douglas K. Price, Ph.D., Warden L. Woodard,
M.D., Chris M. Teigland, M.D. Urologic Oncology 1:226-233,
1995.
6. “Detection of hematogenous dissemination after prostate needle
biopsy by a nested multiplex RT-PCR assay”. DK Price, DR Clontz, WL
Woodard, J Daniels, S Laurent, SJ Peretsman and CM Teigland.
(Published abstract) Proceedings of ASCO 16:340a, 1997.
7. “Detection and clearance of prostate cells subsequent to
ultrasound-guided needle biopsy as determined by multiplex nested
reverse transcription polymerase chain reaction assay”. Douglas K.
Price, Diana R. Clontz, Warden L. Woodard III, Jay S. Kaufman, Jane M.
Daniels, Suzanne J. Stolzenberg, Chris M. Teigland. Urology
52, (2):261-266, 1998.
8. “Thrombomodulin
expression in prostate cancer”. Glasscock LN, Hubbard JS, Lipford ED,
Teigland CM, Price DK. Submitted to Cancer Letters.
9. “Impact of the introduction of laparoscopic nephrectomy within a
community-based teaching hospital”. Kercher KW, Smith TI, Teigland CM,
Irby PB, Eskind LB, Matthews BD, Heniford BT. Surg Endoscopy 2002; 16
(1):S352.
10. “Laparoscopic nephropexy in a patient with nephroptosis of a
solitary kidney”. Carbonell AM, Kercher KW, Irby PB, Teigland CM,
Matthews BD, Heniford BT. Surgical Rounds March 2003, 118-124
11. “Laparoscopic versus Open Nephrectomy in 210 Consecutive
Patients: Outcomes, Cost, and Changes in Practice Patterns”. Kent W.
Kercher MD, B. Todd Heniford MD, Brent D. Matthews MD, Trina I. Smith
BS, Amy E. Lincourt PhD, Daniel H. Hayes MD, Lon B. Eskind MD, Pierce B.
Irby MD, Chris M. Teigland MD. Surg Endoscopy 17:1889-1895,
Oct. 2003.
12.
“Hand-Assisted Laparoscopic Radical Nephrectomy for Renal Cell Carcinoma
with Renal Vein Tumor Thrombus.” Kent W. Kercher MD, Tien H.
Nguyen DO, B. Todd Heniford MD, Pierce B. Irby MD,
Chris M. Teigland MD,
Department of General Surgery and McKay Department of Urology, Carolinas
Medical Center, Charlotte, North Carolina. In review, Surg Lap
Endosc Perc Tech 2003.
13. “Clinical Use of Fluorodeoxyglucose F-18 Positron Emission
Tomography for Detection of Renal Cell Carcinoma.” David E. Kang,
Richard L. White Jr., James H. Zuger, Howell C. Sasser,
Chris M. Teigland.
Journal of Urology 171 (5): 1806-1809, May 2004.
Peer
Reviewed Presentations/Posters:
1. “Potential Hazards of Power Lithotripsy”, Resident Essay Contest, South
Central AUA Section Meeting, Houston,
Texas, 1984
2. “Selective Surgery for Testis Tumors”, Paul C. Peters, Chris M.
Teigland, AUA Meeting, Atlanta, Georgia, 1985
3. “The Effect of Power Lithotripsy
on Renal Parenchyma”, Chris M. Teigland, Ralph V. Clayman, John
H. Childers, Third World Congress on Endourology, New York City, New
York, 1985
4. “Ultrasonic Lithoptripsy, The Risk of Hearing Loss:, Chris M.
Teigland, Ralph V. Clayman, Ross J. Roeser, Third
World Congress on Endourology, New York City, New York, 1985.
5. “Comparative Urodynamic Assessment of Four Different Continent Urinary
Diversion: (Camey, Kock, Ileocecal reservoir, MAINZ pouch)”, Chris M. Teigland, Claus G. Roehrborn,
Arthur Sagalowsky, AUA Meeting, New York City, New York, 1986.
6. “A New Molecular Method to Evaluate Prostate Cancer:
detection of circulating prostate cancer cells by a multiplex reverse
transcriptase polymerase chain reaction assay”, D.K. Price, W. Woodard,
H. Godwin, C.M. Teigland, 45th Annual Meeting of the American
Society of Human Genetics, Minneapolis, MN, October 1995
7. #6 above also presented at the Society for Basic Urologic Research,
Chapel Hill, NC, December 1995.
8. “Prostate Cancer 1996”, CMC Spring Symposium, geriatrics section,
Chris M. Teigland, Charlotte, NC, May 25, 1996
9. “Hematogenous dissemination of prostate cancer cells as the
result of needle biopsy: detection of circulating prostate cells by a
quantitative nested multiplex reverse-transcription PCR assay”, D.K.
Price, J. Daniels, D.R. Clontz, C. M. Teigland. 46th Annual
Meeting of the American Society of Human Genetics, San Francisco, CA,
1995
10. “Thrombomodulin in vivo and in vitro expression and activity
in prostate cancer”, LN Glasscock, JS Hubbard, E Lipford, CM Teigland,
DK Price, 90th American Association of Cancer Research,
Philadelphia, PA, April 1999, 40: Abstract #3023.
11. “Thrombomodulin regulation of prostate cancer invasion, cell
adhesion, and angiogenesis”, LN Glasscock, C. Teigland, ME Perraut, JS Hubbard, DK Price, 91st Annual Meeting of the
AACR, San Francisco, CA, April 2000, 41: Abstract# 1932.
12. “What is the best screening strategy for prostate cancer?”
Family Practice Conference, Renaissance Hotel, Charlotte, NC, May 17,
2000.
13. Poster: D. Dreau, C. Walsh, W.D. Holder, R.L. White, C.M. Teigland.
Use of Dendritic Cells to Develop a Vaccine for Prostate Cancer Patients with Advanced Disease.
Society for Basic Urologic Research, Sanibel Harbor, FL, Sept. 9-12, 2000.
14. Kercher KW, Smith TI, Irby PB, Eskind LB, Matthews BD, Heniford
BT, Teigland CM. Impact of the introduction of laparoscopic nephrectomy within a community-based teaching hospital.
Society of American Gastrointestinal Endoscopic Surgeons. 8th World Congress of Endoscopic
Surgery, New York, NY, March 13-16, 2002.
15. Trina I. Smith, Brent D. Matthews, Chris M. Teigland, B.
Todd Heniford, Kent W. Kercher. Hand-Assisted Surgery Decreases Operative Time for Laparoscopic Nephrectomy. Southeastern
Surgical Congress, Savannah, Georgia, February 7-11, 2003.
16.
Kent W. Kercher, Daniel H. Hayes, Brent D. Matthews, B. Todd
Heniford, Amy E. Lincourt, Pierce B. Irby,
Chris M. Teigland. Laparoscopic Versus Open Nephrectomy: Outcomes And Cost
Analysis In 210 Consecutive Patients. Society of American Gastrointestinal Endoscopic Surgeons, Los Angeles,
California, March 10-15, 2003. (abstract)
17. Kercher KW, Carbonell AM, Harold KL, Irby PB, Matthews BD,
Heniford BT, Teigland CM. Laparoscopic radical nephrectomy for renal cell carcinoma with renal vein tumor thrombus. To
be presented, American College of Surgeons
Annual Congress, Chicago, Illinois, Oct 19-23, 2003. (Video
presentation)
|